The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.
The genomic test is designed to identify benign thyroid nodules in patients with indeterminate fine needle aspiration biopsy results.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.
The agency said it is giving labs 60 additional days to report private payor rates but is still expecting to launch the new clinical lab fee schedule in 2018.
ACLA said the goal of the delay is to redefine "applicable laboratories" and give labs and CMS more time to collect data that will inform market-based pricing.
The company said it now has payor coverage for more than 130 million individuals.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Several MDx firms recently touted BCBS's Evidence Street opinions on their tests as milestones, and Palmetto GBA's MolDx may soon be using its assessments.
Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit.
The firm said it expects that Noridian will similarly confirm its draft local coverage determination, bringing coverage for Percepta to around 35 million.
The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.
ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
EndoPredict is a kit-based RNA expression test that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level, and is set to launch in the US this year.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.
After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.